Neurokinin-1 receptor antagonism for the treatment of cough in lung cancer
Jaclyn Smith (Manchester, United Kingdom), Amelie Harle, Fiona Blackhall, Alex Molassiotis, Kim Holt, Rachel Dockry, Philip Russell, Katy Burns, Ryan Robinson, Mark Birrell, Maria Belvisi, Jaclyn Smith
Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action
Session: Airway pharmacology: drug targets and mode of action
Session type: Poster Discussion
Number: 5060
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Jaclyn Smith (Manchester, United Kingdom), Amelie Harle, Fiona Blackhall, Alex Molassiotis, Kim Holt, Rachel Dockry, Philip Russell, Katy Burns, Ryan Robinson, Mark Birrell, Maria Belvisi, Jaclyn Smith. Neurokinin-1 receptor antagonism for the treatment of cough in lung cancer. Eur Respir J 2016; 48: Suppl. 60, 5060
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
An open-label pilot study of memantine, an N-methyl-D-aspartate receptor antagonist in chronic cough Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014
Pharmacological profile of a novel, potent and oral TRPA1 antagonist. Characterization in a preclinical model of induced cough Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015
Cough receptor sensitivity to capsaicin in patients with lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 104s Year: 2001
Expression of CysLT2 receptors in asthmatic lung, and the roles in bronchoconstriction Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014
Anticholinergic treatment does not affect toll-like receptor 3-induced antiviral immune response in COPD bronchial epithelial cells Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
AZD5069: Pharmacological profile of a CXCR2 antagonist in development for the treatment of respiratory disorders Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014
Repeated-dose pharmacokinetics of once-daily TD-4208, a long-acting muscarinic receptor antagonist (LAMA), in subjects with COPD Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014
H4 receptor antagonits as a potential medication for upper airway cough syndrom Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
An oral selective M3 cholinergic receptor antagonist in COPD Source: Eur Respir J 2006 Oct 01;28(4):772-780 Year: 2006
Low level laser in monotherapy or in combination with leukotriene receptor antagonists in the treatment of allergic lung inflammation Source: International Congress 2015 – Chronic airway disorders: miscellaneous aspects Year: 2015
Therapeutic efficacy of a novel LPA1 receptor antagonist, UD-009, in a bleomycin-induced pulmonary fibrosis model Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016
Anti-inflammatory effects of roflumilast N-oxide and dexamethasone in human bronchial epithelial cells stimulated with toll-like receptor agonists Source: Annual Congress 2013 –The pulmonary epithelium: recent developments Year: 2013
Efficacy and safety of AZD5069, a CXCR2 antagonist, in adult bronchiectasis Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013
Interaction between the Arg16 homozygous genotype, inhaled corticosteroids and long acting beta agonists for asthma exacerbations in children? Leukotriene receptor antagonists to the rescue? Source: Annual Congress 2013 –Asthma and lung development: from genes to environment Year: 2013
Side effects of the leukotriene receptor antagonists in asthmatic children Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014
The inverse agonist propranolol does not confer steroid-sparing activity in persistent asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014
Combined loss of M2 and M3 muscarinic acetylcholine receptor (mAChR) function in mutant mice increases serotonin airway responsiveness (AR) Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014
Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 219s Year: 2004
Alpha-7 nicotinic receptor stimulation reduces airway inflammation in a murine model of asthma Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016
Late Breaking Abstract - The neurokinin-1 receptor antagonist orvepitant improves chronic cough symptoms: results from a Phase 2b trial Source: International Congress 2019 – Highlights in lung function and chronic cough Year: 2019